Cellular therapies and immune reprogramming in inflammatory bowel disease: lessons learned and the promise of CAR T-cell therapy
- 10 November 2026
- journal article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Abstract
Despite major therapeutic advances, inflammatory bowel disease (IBD) remains incurable, and many patients experience primary non-response, secondary loss of response, progressive bowel damage, or lifelong dependence on immunomodulatory therapy. Cellular immunotherapies offer the possibility of moving beyond chronic immune suppression toward durable immune reprogramming. Earlier approaches in IBD, including hematopoietic stem cell transplantation, mesenchymal stem cells, and regulatory T-cell–based therapies, have provided important proof-of-concept but have been limited by toxicity, inconsistent efficacy, local rather than systemic effects, or unresolved manufacturing and durability challenges. Chimeric antigen receptor (CAR) T-cell therapy represents the next-generation strategy that combines potent immune remodeling with antigen-specific targeting. Initially developed for hematological malignancies, CAR T cells have recently shown striking efficacy in refractory autoimmune diseases, particularly through CD19-mediated depletion of B-lineage cells and induction of drug-free remission. In ulcerative colitis, renewed interest in B cells has been driven by evidence of plasmablast expansion, IgG-skewed humoral responses, anti-integrin αvβ6 autoantibodies, and the limitations of conventional anti-CD20 depletion. The first reported case of multidrug-resistant ulcerative colitis treated with CD19 CAR T cells demonstrated rapid clinical, biochemical, endoscopic, and histological remission, providing proof-of-concept for deep B-cell targeting in IBD. However, major uncertainties remain, including long-term durability, relapse after B-cell reconstitution, safety, cost, feasibility, and the risk of CAR T-associated gastrointestinal toxicity. Prospective trials with mechanistic mucosal monitoring are now needed to define the therapeutic potential and appropriate positioning of CAR-based strategies in IBD.Funding Information
- Cleveland Combined Training Program in Digestive Disease Sciences through the institutional
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- ECCO Grant 2026 (PROP-3376)
This publication has 35 references indexed in Scilit:
- 33 CAR T-CELL THERAPY AND ULCERATIVE COLITIS ACTIVITY: BASELINE TREATMENT EXPOSURE AND POST-INFUSION DE-ESCALATION IN A MULTICENTER REAL-WORLD COHORTGastroenterology, 2026
- 25 MULTI-OMIC PROFILING OF CAR-T ENTERITIS REVEALS DISTINCT PATHOGENIC MECHANISMS OF CAR+ T CELL–MEDIATED TISSUE INJURYGastroenterology, 2026
- Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Monogenic Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2025
- Relapse after anti-CD19 CAR T-cell therapy in a patient with severe rheumatoid arthritis and multiple sclerosis effectively treated by autologous stem cell transplantationAnnals of the Rheumatic Diseases, 2025
- HSCT: How Does It Work?2023
- Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trialThe Lancet Gastroenterology & Hepatology, 2017
- Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trialThe Lancet, 2016
- Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn DiseaseJAMA, 2015
- A Phase I Clinical Trial of the Treatment of Crohn's Fistula by Adipose Mesenchymal Stem Cell TransplantationDiseases of the Colon & Rectum, 2005
- Case of crohn's disease in bone marrow transplantationAmerican Journal of Hematology, 1993